StemCell Therapy

Since PDS Biotechnology Corporation (NASDAQ:PDSB) and Axsome Therapeutics Inc. (NASDAQ:AXSM) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation of both companies.

Earnings & Valuation

Demonstrates PDS Biotechnology Corporation and Axsome Therapeutics Inc. earnings per share, gross revenue and valuation.

Profitability

Table 2 demonstrates the return on equity, net margins and return on assets of PDS Biotechnology Corporation and Axsome Therapeutics Inc.

Risk & Volatility

PDS Biotechnology Corporation has a 2.42 beta, while its volatility is 142.00% which is more volatile than Standard and Poors 500. From a competition point of view, Axsome Therapeutics Inc. has a 2.65 beta which is 165.00% more volatile compared to Standard and Poors 500.

Liquidity

PDS Biotechnology Corporations Current Ratio is 5 while its Quick Ratio is 5. On the competitive side is, Axsome Therapeutics Inc. which has a 5.7 Current Ratio and a 5.7 Quick Ratio. Axsome Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to PDS Biotechnology Corporation.

Analyst Ratings

The next table highlights the given recommendations and ratings for PDS Biotechnology Corporation and Axsome Therapeutics Inc.

The consensus target price of PDS Biotechnology Corporation is $8.5, with potential upside of 201.42%. Competitively Axsome Therapeutics Inc. has a consensus target price of $48, with potential upside of 5.66%. The information presented earlier suggests that PDS Biotechnology Corporation looks more robust than Axsome Therapeutics Inc. as far as analyst belief.

Insider & Institutional Ownership

Roughly 28.3% of PDS Biotechnology Corporation shares are owned by institutional investors while 46.3% of Axsome Therapeutics Inc. are owned by institutional investors. About 6.5% of PDS Biotechnology Corporations share are owned by insiders. Comparatively, Axsome Therapeutics Inc. has 2.2% of its share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year PDS Biotechnology Corporation has weaker performance than Axsome Therapeutics Inc.

Summary

On 6 of the 11 factors Axsome Therapeutics Inc. beats PDS Biotechnology Corporation.

Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the management of central nervous system (CNS) disorders. The companys product candidates include AXS-05 that is in Phase III trial for the treatment of treatment resistant depression and Alzheimers disease agitation; and AXS-02, which is in Phase III trial to treat complex regional pain syndrome, knee osteoarthritis related to bone marrow lesions, and chronic low back pain related to Modic changes. It is also developing AXS-06, a preclinical product candidate for CNS disorders, including chronic pain. The company was founded in 2012 and is based in New York, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Follow this link:
Comparison of PDS Biotechnology Corporation (PDSB) and Axsome Therapeutics Inc. (NASDAQ:AXSM) - The Broch Herald

This entry was posted on December 9, 2019 at 7:47 am and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |